| # | Country | Total Patents | |
|---|---|---|---|
| #1 | United States | 5 | |
| #2 | Japan | 4 | |
| #3 | China | 2 | |
| #4 | Australia | 1 | |
| #5 | EPO (European Patent Office) | 1 | |
| #6 | Israel | 1 | |
| #7 | Republic of Korea | 1 | |
| #8 | New Zealand | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Biotechnology | |
| #3 | Measurement | |
| #4 | Agriculture |
| # | Technology | |
|---|---|---|
| #1 | Medical preparations | |
| #2 | Peptides | |
| #3 | Therapeutic chemical compounds | |
| #4 | Analysing materials | |
| #5 | Microorganisms | |
| #6 | Animal care |
| # | Name | Total Patents |
|---|---|---|
| #1 | Zheng Pan | 15 |
| #2 | Zheng Xincheng | 11 |
| #3 | Wu Wei | 11 |
| #4 | Liu Yang | 11 |
| #5 | Liu Yan | 5 |
| #6 | Zhang Yan | 2 |
| #7 | Liu Mingyue | 2 |
| #8 | Devenport Martin | 2 |
| #9 | Tang Fei | 2 |
| #10 | Du Xuexiang | 2 |
| Publication | Filing date | Title |
|---|---|---|
| US2021047410A1 | Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy | |
| US2021040212A1 | Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects | |
| US2013231464A1 | Methods of use of soluble cd24 for therapy of rheumatoid arthritis |